Can effects of antidepressants in patients with mild depression be considered as clinically significant?

详细信息	查看全文 | 推荐本文 |

• 作者：Ulrich Hegerl^a ; ^{Ulrich.Hegerl@medizin.uni-leipzig.de} ; Antje-Kathrin Allgaier^b ; Verena Henkel^c ; Roland Mergl^a
• 关键词：Antidepressants ; Clinical trial ; Depression ; Placebo&ndash ; verum difference ; Hamilton Depression Rating Scale
• 刊名：Journal of Affective Disorders
• 出版年：2012
• 期刊代码：141_01650327
• 类别：med
• 出版时间：May, 2012
• 卷：138
• 期：3
• 页码：183-191
• 文件大小：361 K

摘要

Background

How to define clinical significance of antidepressants has become a matter of far-reaching clinical and regulatory consequences. A mean difference of at least 3 points on the Hamilton Depression Rating Scale (HAMD-17) between active treatment and placebo has been proposed as cut-off score for clinical significance in antidepressant trials.

Objective

We aimed to present arguments that this, and other commonly used related approaches to establish clinical significance are likely to be misleading and risky depriving patients with mild depression of efficient treatments.

Methods

These problems are exemplified with the data from a randomized placebo-controlled five-arm clinical trial with primary care patients with milder depressive syndromes (MIND-study).

Results and conclusions

Designs for studying clinical significance have to be distinguished from those assessing efficacy. Moreover, evaluation of the clinical significance of psychotherapy as a possible alternative to antidepressants faces the problem of how to define a valid control group where blinding of neither therapists nor patients is possible.